Danaher (NYSE:DHR) Releases Earnings Results, Beats Estimates By $0.20 EPS

Danaher (NYSE:DHR) released its quarterly earnings results on Tuesday. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20, Briefing.com reports. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 EPS.

Danaher Price Performance

NYSE:DHR traded down $3.36 on Wednesday, reaching $249.75. The stock had a trading volume of 1,103,403 shares, compared to its average volume of 2,755,977. The company has a market capitalization of $184.95 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 3.96 and a beta of 0.83. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average price of $248.95 and a 200-day moving average price of $230.64.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s payout ratio is 16.90%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the sale, the director now owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 over the last ninety days. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DHR. Barclays lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Royal Bank of Canada lifted their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.